News
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
Eli Lilly (LLY) climbed to new record highs in the final week of June, driven by strong sales of its weight-loss drugs. Away from that spotlight, the drugmaker made changes to a smaller corner of its business in its second-largest market. On June 30, Lilly agreed to hand a Chinese partner full ...
Medicare is now covering weight-loss drugs for some seniors, in a win for patients. For Wall Street, the math is trickier.
Millions of older Americans are on the cusp of more affordable access to popular weight-loss drugs when a major Medicare coverage expansion kicks in July 1.
Earnings are coming up for Nike as the company tries to engineer a turnaround, but Nike stock continues to plumb 52-week lows.
(Bloomberg) -- Moving from Pfizer Inc. to Nike Inc. may seem like an unusual career shift for a finance chief. For David Denton, it marks a return to the consumer sector after four years in pharmaceuticals.Most Read from BloombergInvestor Who Scored 900% Win in 2008 Crisis Has New Big Short BetGrand Ole Opry House Up For Sale by Owner Ryman HospitalityMicron Shares Soar After AI-Fueled Forecast Shatters ProjectionsStocks Slide as Wall Street Gets AI Wake-Up Call: Markets WrapStocks Erase Gains a
A coalition of employers and state governments says it is developing a sweeping strategy to help workers respond to the AI age.
When Dave Ricks became chief executive officer of Eli Lilly & Co. in 2017, he was facing an industry under siege. Americans held drug companies in lower esteem than airlines, law firms and even the federal government. President Donald Trump, then starting his first term, was excoriating them for their high prices. A mounting number of reports showed that soaring costs were even forcing some diabetics to ration insulin. Ricks, the 11th CEO in Lilly's 150-year history, concedes that one was a public-relations nightmare. Almost a decade later, the mood at Lilly has shifted dramatically. The company's hit diabetes shot, Mounjaro, and obesity shot, Zepbound, have transformed its fortunes and, in many ways, its public image. We speak with Madison Muller, Bloomberg News Healthcare Reporter, for a closer look.
Doctors are looking for better options given the growing awareness of the serious health risks tied to childhood obesity.
Eli Lilly's spate of acquisitions is building out multiple areas of its pipeline at once.
Johnson & Johnson has no plans to enter the booming obesity market, opting instead to focus on diseases such as cancer, CEO Joaquin Duato said in an interview for an upcoming episode of The David Rubenstein Show: Peer to Peer Conversations. The comments set J&J apart from many of its rivals that are trying to develop or acquire obesity medicines following blockbuster weight-loss drugs from Eli Lilly & Co. and Novo Nordisk.
(Bloomberg) -- It was 180 degrees off the hot trade on Wall Street. Most Read from BloombergRead the 14-Point Draft Memorandum Between the US and IranModi Warns of ‘Shortage of Trust’ Ahead of Trump MeetingIran’s Deputy Foreign Minister Confirms Deal Reached With USNetanyahu Pays a Political Price for Trump’s Iran DealUS Set to Offer Iran Broad Financial Gains in Peace DealSnub Nvidia Corp., the soaring king of artificial intelligence chips. Embrace Adobe Inc., a sinking casualty of AI disruptio
<body><p>STORY: Big pharma is receiving pushback from European capitals on drug pricing. </p><p>So they’re turning to a playbook that brought them success in the UK.</p><p>Making threats to pull investment plans to pressure policymakers. </p><p>The industry notched a win when the British government agreed to increase medicine spending as part of a broader deal to avoid U.S.-imposed tariffs. </p><p>The latest nation to face pressure is Germany, which has been debating legislation to tighten spending on medicines. </p><p>A Reuters European Pharma correspondent Maggie Fick said pressure in the last week has ramped up. </p><p>"The CEO of Pfizer wrote a letter to the German chancellor warning that their future investments in the country may be at risk over these proposed changes to pricing laws."</p><p>Meanwhile, AstraZeneca warned that it may not launch new medicines in Germany if these changes go ahead.</p><p>Earlier in June, Eli Lilly announced it would halve a planned $2.7 billion investment, also citing the proposed legislation. </p><p>This bid to cap costs has centered Germany in a broader tussle between drugmakers and European governments that began several months ago.</p><p>That tension has been sharpened by the impact on Europe of U.S. President Donald Trump's pricing push.</p><p>This aims to tie prescription medicine prices in the lucrative U.S. market to lower prices elsewhere, including in Europe.</p><p>Major drugmakers have struck deals with the White House to lower drug costs in exchange for tariff exemptions, adding to pressure for increasing prices elsewhere.</p></body>
Eli Lilly (LLY) became the first pharmaceutical company to cross a $1 trillion market valuation in November last year, carried largely by its highly lucrative obesity and diabetes medications, such as Mounjaro and Zepbound. Now the same demand that built that fortune is creating friction with the ...
Gain insight on Roche, Zealand Pharma and more in the latest Market Talks covering the health care sector.
The European stock markets were modestly higher in Tuesday trading as the markets reacted positively
Led by top holdings like Popular, East West Bancorp and Zions, KRE ETF is in buy range as the financial ETF flashes signs of strength.
Hyderabad-based Electronics Mart India is looking to diversify away from the technology hub as concerns grow that potential AI-triggered job losses could hurt consumer spending, a top executive said. The retailer gets about 60% of its revenue from Hyderabad, which hosts offices of global companies such as JPMorgan Chase and Eli Lilly, and Indian IT majors Wipro and Infosys. Around a fifth of its stores in Hyderabad are located in neighbourhoods where the majority of the residents are software employees.
Investing.com -- Elon Musk’s SpaceX on Thursday said that it has priced its initial public offering at $135 per share on Thursday, raising $75 billion in the largest IPO in U.S. history.
Led by former Loxo Oncology CEO Josh Bilenker, the startup now has a trio of cancer drugs in early-stage testing and more following closely behind.
(Bloomberg) -- The Pentagon accused some of China’s biggest companies, including Alibaba Group Holding Ltd., Baidu Inc. and BYD Co. of supporting the Chinese military, doubling down on an earlier decision to label crown jewels of the country’s corporate world as threats to US national security.Most Read from BloombergHouse Republican Says Hegseth’s D-Day Remarks ‘Inappropriate’LA Mayor Race Flips as Socialist Beats Reality TV Star PrattTrump Says He, Not Congress, Is in Charge of Kennedy Center
Infectious disease could fuel Eli Lilly's next growth phase.
A late-stage trial showed retatrutide was effective in weight loss and in alleviating obesity-linked conditions.
More employers are requiring weigh-ins, app tracking and health coaching before approving GLP-1s for losing weight—or dropping coverage altogether.
Eli Lilly's (LLY) chairman and CEO Dave Ricks told German business newspaper Handelsblatt that Lilly would halve its planned investment in Germany, cutting its original 2.3 billion euro ($2.67 billion) commitment by roughly 50%. Reuters reported the announcement on June 3, 2026. The pullback lands ...
Eli Lilly signed a collaboration and licensing agreement worth up to $1.9 billion with Ascidian Therapeutics to research and develop kidney-disease treatments.
Eli Lilly (LLY) just did something worth paying attention to. With CVS Caremark announcing coverage of both Zepbound and newly approved Foundayo starting this summer, all three of the largest U.S. pharmacy benefit managers now cover Lilly’s complete obesity medicine portfolio. That’s a clean sweep ...